Third-generation EGFR and ALK inhibitors: mechanisms of resistance and management
AJ Cooper, LV Sequist, JJ Lin - Nature Reviews Clinical Oncology, 2022 - nature.com
The discoveries of EGFR mutations and ALK rearrangements as actionable oncogenic
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
drivers in non-small-cell lung cancer (NSCLC) has propelled a biomarker-directed treatment …
Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance
K Fu, F **e, F Wang, L Fu - Journal of Hematology & Oncology, 2022 - Springer
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR …
Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling
Drug resistance in cancer is often linked to changes in tumor cell state or lineage, but the
molecular mechanisms driving this plasticity remain unclear. Using murine organoid and …
molecular mechanisms driving this plasticity remain unclear. Using murine organoid and …
Overcoming therapy resistance in EGFR-mutant lung cancer
Tyrosine kinase inhibitors (TKIs) have dramatically changed the clinical prospects of patients
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
with non-small cell lung cancer harboring epidermal growth factor receptor (EGFR) …
Acquired Resistance to KRASG12C Inhibition in Cancer
Background Clinical trials of the KRAS inhibitors adagrasib and sotorasib have shown
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
promising activity in cancers harboring KRAS glycine-to-cysteine amino acid substitutions at …
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
J Chmielecki, JE Gray, Y Cheng, Y Ohe… - Nature …, 2023 - nature.com
Osimertinib, an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI),
potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance …
potently and selectively inhibits EGFR-TKI-sensitizing and EGFR T790M resistance …
Targeting KRAS mutant cancers: from druggable therapy to drug resistance
C Zhu, X Guan, X Zhang, X Luan, Z Song, X Cheng… - Molecular cancer, 2022 - Springer
Abstract Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) is the most frequently
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …
mutated oncogene, occurring in a variety of tumor types. Targeting KRAS mutations with …
Efficacy and Safety of Patritumab Deruxtecan (HER3-DXd) in EGFR Inhibitor–Resistant, EGFR-Mutated Non–Small Cell Lung Cancer
PA Jänne, C Baik, WC Su, ML Johnson, H Hayashi… - Cancer discovery, 2022 - AACR
Receptor tyrosine-protein kinase ERBB3 (HER3) is expressed in most EGFR-mutated lung
cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an …
cancers but is not a known mechanism of resistance to EGFR inhibitors. HER3-DXd is an …
Acquired resistance to immune checkpoint inhibitors
Immune checkpoint inhibitors (ICIs) have rapidly altered the treatment landscape for multiple
tumor types, providing unprecedented survival in some patients. Despite the characteristic …
tumor types, providing unprecedented survival in some patients. Despite the characteristic …
[HTML][HTML] Mechanisms and management of 3rd‑generation EGFR‑TKI resistance in advanced non‑small cell lung cancer
J He, Z Huang, L Han, Y Gong… - … journal of oncology, 2021 - spandidos-publications.com
Targeted therapy with epidermal growth factor receptor (EGFR)‑tyrosine kinase inhibitors
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …
(TKIs) is a standard modality of the 1st‑line treatments for patients with advanced EGFR …